NCT04824898

The Use of Injectable Plasma Versus the Use of Simvastatin Gel in Surgical Management of Bony Defect in Dentistry

Status unknown Phase 1 Last updated 1 April 2021

What this trial tests

Phase 1 trial testing Simvastatin in Intra-bony Pockets in 24 participants. Status unknown.

Timeline

20 January 2021

Primary endpoint
20 September 2022

20 September 2022

Quick facts

Lead sponsor	Ain Shams University
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	20 January 2021
Primary completion	20 September 2022
Estimated completion	20 September 2022
Sites	1 location across Egypt

Drugs / interventions tested

• Simvastatin (simvastatin) — full drug profile →
• injectable plasma rich fibrin

Conditions studied

• Intra-bony Pockets — all drugs for Intra-bony Pockets →

Sponsor

Ain Shams University

Who can join

Adults 25 to 40, any sex, with Intra-bony Pockets. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Simvastatin (SMV) is one of the family members of statins, it has been showed in many previous studies that the simvastatin when dissolved with methylcellulose in situ gel with a concentration of 1.2% (SMV) approximately, can have a significant decrease in the pocket depth, regain the clinical attachment loss (CAL), and improve the bone level.

and the platelets concentrate has been introduced which is the injectable plasma rich fibrin (I-PRF), as it contains platelets and leukocytes, stem cells and endothelial cells that why it is called "blood concentrate ". So, it is proposed as treatment option in different periodontal procedures such as treatment of intra-bony defects,

Publications & conference data

No peer-reviewed publications indexed yet for this trial.